Immunosuppression in lung transplantation.

Lung transplantation can be a life-saving procedure for those with end-stage lung diseases. Unfortunately, long term graft and patient survival are limited by both acute and chronic allograft rejection, with a median survival of just over 6 years. Immunosuppressive regimens are employed to reduce the rate of rejection, and while protocols vary from center to center, conventional maintenance therapy consists of triple drug therapy with a calcineurin inhibitor (cyclosporine or tacrolimus), antiproliferative agents [azathioprine (AZA), mycophenolate, sirolimus (srl), everolimus (evl)], and corticosteroids (CS). Roughly 50% of lung transplant centers also utilize induction therapy, with polyclonal antibody preparations [equine or rabbit anti-thymocyte globulin (ATG)], interleukin 2 receptor antagonists (IL2RAs) (daclizumab or basiliximab), or alemtuzumab. This review summarizes these agents and the data surrounding their use in lung transplantation, as well as additional common and novel therapies in lung transplantation. Despite the progression of the management of lung transplant recipients, they continue to be at high risk of treatment-related complications, and poor graft and patient survival. Randomized clinical trials are needed to allow for the development of better agents, regimens and techniques to address above mentioned issues and reduce morbidity and mortality among lung transplant recipients.

[1]  H. Reichenspurner,et al.  Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  Scott B. Johnson,et al.  Effect of inhaled tacrolimus on ischemia reperfusion injury in rat lung transplant model. , 2013, The Journal of thoracic and cardiovascular surgery.

[3]  G. Verleden,et al.  Pirfenidone: A Potential New Therapy for Restrictive Allograft Syndrome? , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  C. Neurohr,et al.  Pirfenidone: a potential therapy for progressive lung allograft dysfunction? , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  T. Welte,et al.  Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Parulekar,et al.  Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  P. Jaksch,et al.  A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  H. Reichenspurner,et al.  Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  G. Visner,et al.  Inhibitory Effects of Pirfenidone on Dendritic Cells and Lung Allograft Rejection , 2012, Transplantation.

[11]  G. Verleden,et al.  Anti-Inflammatory and Immunomodulatory Properties of Azithromycin Involved in Treatment and Prevention of Chronic Lung Allograft Rejection , 2012, Transplantation.

[12]  P. Friend,et al.  B Cell Repopulation After Alemtuzumab Induction—Transient Increase in Transitional B Cells and Long-Term Dominance of Naïve B Cells , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  R. Hachem.  Antibody-mediated lung transplant rejection , 2012, Current Respiratory Care Reports.

[14]  S. Syrjälä,et al.  Effect of simvastatin on development of obliterative airway disease: an experimental study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  J. Golden,et al.  Use of sublingual tacrolimus in lung transplant recipients. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  A. Solé,et al.  A retrospective 12-month study of conversion to everolimus in lung transplant recipients. , 2011, Transplantation proceedings.

[17]  T. Welte,et al.  Graft-Protective Effects of the HMG-CoA Reductase Inhibitor Pravastatin After Lung Transplantation— A Propensity Score Analysis With 23 Years of Follow-Up , 2011, Transplantation.

[18]  A. Alba,et al.  Long-term use of everolimus in lung transplant patients. , 2011, Transplantation proceedings.

[19]  M. Dew,et al.  Five-year outcomes with alemtuzumab induction after lung transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  M. Federica,et al.  Clinical and immunological evaluation of 12‐month azithromycin therapy in chronic lung allograft rejection , 2011, Clinical transplantation.

[21]  Alan B. Watts,et al.  Preclinical evaluation of tacrolimus colloidal dispersion for inhalation. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  G. Verleden,et al.  Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  H. Mansour,et al.  Aerosolized tacrolimus: a case report in a lung transplant recipient. , 2010, Transplantation proceedings.

[24]  C. Gluud,et al.  Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials , 2010, European Journal of Clinical Pharmacology.

[25]  G. Patterson,et al.  Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  G. Verleden,et al.  A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation , 2010, European Respiratory Journal.

[27]  G. Patterson,et al.  Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  H. Fagertun,et al.  Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial , 2010, Transplantation.

[29]  G. Patterson,et al.  The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  A. Glanville.  Antibody-mediated rejection in lung transplantation: myth or reality? , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  B. Griffith,et al.  Early outcomes using alemtuzumab induction in lung transplantation. , 2010, Interactive cardiovascular and thoracic surgery.

[32]  Scott B. Johnson,et al.  Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. , 2010, International journal of pharmaceutics.

[33]  T. Machuca,et al.  Acute humoral rejection in a lung recipient: reversion with bortezomib. , 2010, Transplantation.

[34]  G. Visner,et al.  Pirfenidone Inhibits T-Cell Activation, Proliferation, Cytokine and Chemokine Production, and Host Alloresponses , 2009, Transplantation.

[35]  B. Reichart,et al.  Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[36]  J. Jamart,et al.  Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. , 2009, Transplantation proceedings.

[37]  H. Unruh,et al.  Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. , 2008, Canadian respiratory journal.

[38]  L. Snyder,et al.  Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[39]  E. Trulock,et al.  The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry , 2008, Clinical transplantation.

[40]  G. Keren,et al.  The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. , 2008, Atherosclerosis.

[41]  Philip Smith,et al.  Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. , 2008, The Journal of thoracic and cardiovascular surgery.

[42]  T. Welte,et al.  Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2008, Transplantation.

[43]  G. Patterson,et al.  A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[44]  G. Klintmalm,et al.  Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity , 2007, Clinical transplantation.

[45]  S. Chadban,et al.  Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[46]  N. Perico,et al.  Regulatory T cells and T cell depletion: role of immunosuppressive drugs. , 2007, Journal of the American Society of Nephrology : JASN.

[47]  Jennifer L. Taylor,et al.  Critical Care Perspective on Immunotherapy in Lung Transplantation , 2006, Journal of intensive care medicine.

[48]  G. Verleden,et al.  Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. , 2006, American journal of respiratory and critical care medicine.

[49]  R. Levy,et al.  Limited Sampling Strategy for Predicting Area Under the Concentration‐Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients , 2006, Pharmacotherapy.

[50]  R. Malthaner,et al.  Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  H. Arendrup,et al.  The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[52]  P. Barnes.  How corticosteroids control inflammation: Quintiles Prize Lecture 2005 , 2006, British journal of pharmacology.

[53]  R. Speich,et al.  Comparison of Mycophenolate Mofetil and Azathioprine for Prevention of Bronchiolitis Obliterans Syndrome in De Novo Lung Transplant Recipients , 2006, Transplantation.

[54]  B. Griffith,et al.  A randomized trial of inhaled cyclosporine in lung-transplant recipients. , 2006, The New England journal of medicine.

[55]  G. Snell,et al.  Everolimus Versus Azathioprine in Maintenance Lung Transplant Recipients: An International, Randomized, Double‐Blind Clinical Trial , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[56]  M. Zamora,et al.  Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[57]  Gerald J Berry,et al.  Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[58]  M. J. Alvarez,et al.  Rapamycin in lung transplantation. , 2005, Transplantation proceedings.

[59]  M. de la Torre,et al.  Comparative study of basiliximab treatment in lung transplantation. , 2005, Transplantation proceedings.

[60]  D. Zander,et al.  Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[61]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.

[62]  M. Kamler,et al.  Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[63]  P. Jaksch,et al.  Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[64]  N. Giannetti,et al.  Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[65]  M. Estenne,et al.  Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[66]  M. Kramer,et al.  Successful steroid withdrawal in lung transplant recipients: result of a pilot study. , 2005, Respiratory medicine.

[67]  M. Hartwig,et al.  Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. , 2005, Human immunology.

[68]  S. Bhorade,et al.  Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[69]  M. Kramer,et al.  Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. , 2005, Kidney international.

[70]  J. Preiksaitis,et al.  A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[71]  J. Lordan,et al.  Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. , 2005, American journal of respiratory and critical care medicine.

[72]  M. Spiteri,et al.  Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. , 2005, American journal of respiratory cell and molecular biology.

[73]  G. Verleden,et al.  AZITHROMYCIN THERAPY FOR PATIENTS WITH BRONCHIOLITIS OBLITERANS SYNDROME AFTER LUNG TRANSPLANTATION , 2004, Transplantation.

[74]  B. Meiser,et al.  Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[75]  R. Balshaw,et al.  New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta‐Analysis , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[76]  B. Griffith,et al.  Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans , 2004, European Respiratory Journal.

[77]  G. Patterson,et al.  Comparison of basiliximab and antithymocyte globulin as induction agents after lung transplantation , 2004 .

[78]  A. Havryk,et al.  Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation1 , 2004, Transplantation.

[79]  J. Orens,et al.  Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. , 2003, American journal of respiratory and critical care medicine.

[80]  M. Hertz,et al.  Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation , 2003, Transplantation.

[81]  K. McCurry,et al.  Statin use is associated with improved function and survival of lung allografts. , 2003, American journal of respiratory and critical care medicine.

[82]  H. Reichenspurner,et al.  Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. , 2003, The Journal of thoracic and cardiovascular surgery.

[83]  B. Cahill,et al.  Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[84]  D. Holt.  Monitoring mycophenolic acid , 2002, Annals of clinical biochemistry.

[85]  S. Bell,et al.  Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial , 2002, Thorax.

[86]  R. J. Dumont,et al.  A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[87]  D. Zander,et al.  RESULTS OF A RANDOMIZED, PROSPECTIVE, MULTICENTER TRIAL OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN THE PREVENTION OF ACUTE LUNG ALLOGRAFT REJECTION1 , 2001, Transplantation.

[88]  H. Reichenspurner,et al.  Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[89]  A. Husain,et al.  LOW RATE OF ACUTE LUNG ALLOGRAFT REJECTION AFTER THE USE OF DACLIZUMAB, AN INTERLEUKIN 2 RECEPTOR ANTIBODY , 2001, Transplantation.

[90]  H. Bittner,et al.  HYPERACUTE REJECTION IN SINGLE LUNG TRANSPLANTATION—CASE REPORT OF SUCCESSFUL MANAGEMENT BY MEANS OF PLASMAPHERESIS AND ANTITHYMOCYTE GLOBULIN TREATMENT , 2001, Transplantation.

[91]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[92]  S. Matsuda,et al.  Mechanisms of action of cyclosporine. , 2000, Immunopharmacology.

[93]  F. Oppenheimer.  Steroid withdrawal in renal transplant recipients. , 2000, Transplantation proceedings.

[94]  J. Gaynor,et al.  Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. , 1999, Chest.

[95]  J. Parameshwar,et al.  Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. , 1999, Therapeutic drug monitoring.

[96]  Jean‐Paul Squifflet,et al.  The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation , 1998, Clinical pharmacology and therapeutics.

[97]  S. Sherwood,et al.  Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. , 1998, Transplantation proceedings.

[98]  M. Rosenthal,et al.  Long-term azithromycin may improve lung function in children with cystic fibrosis , 1998, The Lancet.

[99]  F. Martinez,et al.  Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. , 1997, The Annals of thoracic surgery.

[100]  B. Griffith,et al.  Dose-related reversal of acute lung rejection by aerosolized cyclosporine. , 1997, American journal of respiratory and critical care medicine.

[101]  B. Griffith,et al.  Aerosolized cyclosporine in lung recipients with refractory chronic rejection. , 1996, American journal of respiratory and critical care medicine.

[102]  B. Griffith,et al.  A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. , 1994, Transplantation.

[103]  B. Kahan,et al.  Cyclosporine Monitoring in Renal Transplantation: Area Under the Curve Monitoring Is Superior to Trough‐Level Monitoring , 1989, Therapeutic drug monitoring.

[104]  D. Nguyen,et al.  Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients. , 2014, The Annals of thoracic surgery.

[105]  A. Angelini,et al.  Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[106]  A. Glanville,et al.  Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[107]  A. Haverich,et al.  Contributions from the European Respiratory Monograph Series "lung Transplantation" Edited Immunosuppressive Therapy after Human Lung Transplantation , 2003 .

[108]  H. Valantine,et al.  Calcineurin Inhibitors and Post-Transplant Hyperlipidaemias , 2001, Drug safety.